Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...

The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a stellar 43% in a week. Much of this move came after the company’s controversial Super Bowl commercial ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Bullish option flow detected in Hims and Hers Health with 70,176 calls trading, 5x expected, and implied vol increasing almost 17 points to 144.53%. Feb-25 36 calls and Feb-25 70 calls are the ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 156. ...